Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)
Anna Berg(Stichting Kinderoncologie Nederland), Elisabeth T Korthof(Europdonor Foundation), Margreet H van Weel Sipman(Stichting Kinderoncologie Nederland), Marry M. van den Heuvel‐Eibrink(Princess Máxima Center), C Korbijn(Stichting Kinderoncologie Nederland), Theo Stijnen(Leiden University Medical Center), Marrie C.A. Bruin(Stichting Kinderoncologie Nederland), Willem A. Kamps(Pediatric Oncology Group), Elisabeth R. van Wering(Stichting Kinderoncologie Nederland), Karin van der Pal(Stichting Kinderoncologie Nederland), J.F. van der Weerden(Stichting Kinderoncologie Nederland), Eva van den Berg(Royal Hospital for Children), Henk van den Berg(Emma Kinderziekenhuis), Jos P.M. Bökkerink(Radboud University Nijmegen)
Cited by 250
Related Papers
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932
Evidence Based Selection of Housekeeping Genes
|PLoS ONE|2007|772
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599